ax Pharmaceuticals Ltd. (TASE: BNDX), an Israeli biopharmaceutical company at the forefront of global efforts towards the development of a Universal Influenza Vaccine, today announced that it has begun to immunize subjects in a Phase IIa clinical trial of the Multimeric-001 Universal Flu Vaccine candidate. The study will evaluate the safety and immunogenicity of the Multimeric-001 vaccine. The vaccine is comprised of a unique, proprietary combination of conserved epitopes from influenza virus proteins, designed to stimulate both humoral (antibody-mediated) and cell-mediated immunity against both Type A and Type B influenza strains, and is thereby intended to provide protection against all seasonal and pandemic flu strains.
The Phase IIa study is a randomized, double-blind, placebo-controlled, multi-center, safety and immunogenicity study in 200 healthy volunteers. The study is being conducted at two clinical research centers in Israel, the Hadassah Clinical Research Center at Hadassah University Hospital in Jerusalem ("Hadassah") and the Tel Aviv Sourasky Medical Center ("Ichilov"). The principal investigators conducting the clinical trial are Prof. Yoseph Caraco, Director of the Clinical Research Center at Hadassah and Dr. Jacob Atsmon, Director of the Clinical Research Center at Ichilov.
Dr. Ron Babecoff, BiondVax's President and CEO, said, "The commencement of this Phase IIa study is a major milestone in the clinical development of the Multimeric-001 universal influenza vaccine. After the excellent results we achieved in our two previous Phase I/II trials, in which the Multimeric-001 vaccine was shown to be safe and immunogenic in both younger and older adults, we are excited to be embarking on this new important phase in the development of the universal influenza vaccine."
In the study, a total of 200 subjects, both male and female, 18-49 years old, will be divided into six groups, enabling the assessment of the s
Page: 1 2 3 4 5 6 7 8 Related medicine technology :1
|SOURCE BiondVax Pharmaceuticals Ltd.|
Copyright©2010 PR Newswire.
All rights reserved
. Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals Universal Flu Vaccine2
. LIG Assets, Inc. Begins Distribution and Marketing of Unique CPAP Mask Cleaner3
. China PharmaHub Corp. Begins Trading Under Stock Symbol CPHB Instead of WRLC4
. Hospira Begins Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients5
. Sysmex America Begins Distribution of CellaVision® DM12006
. Renhuang Begins Trading on NYSE Amex7
. Par Pharmaceutical Begins Shipment of Generic Zegerid®8
. Curemark Begins Autism Trials at Two More Sites9
. ThromboGenics and BioInvent to Receive EUR10 Million Milestone as Partner Roche Begins New Clinical Study with TB-40310
. The Wellcore System Begins Shipping Featuring the Most Advanced Automatic Fall Detection Available11
. ADVENTRX Reverse Split Effective; Trading on Adjusted Basis Begins Today